Volume 30, Number 9—September 2024
CME ACTIVITY - Research
Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1
Viivi Nevanlinna
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Table 1
Clinical manifestations and disease severity in patients with Streptococcus dysgalactiae subspecies equisimilis bacteremia during November 2015–November 2019, Finland*
| Infection type† | Nonsevere disease, n = 142 | Severe disease, n = 17 | p value |
|---|---|---|---|
| Skin/soft tissue infection | 107 (75) | 10 (59) | 0.154 |
| Cellulitis | 103 (73) | 7 (41) | 0.008 |
| Purulent skin infection | 27 (19) | 4 (24) | 0.746 |
| Necrotizing fasciitis |
1 (1) |
3 (18) |
0.004 |
| Deep abscess | 13 (9) | 2 (12) | 0.664 |
| Bursitis |
2 (1) |
0 |
NA |
| Bone and joint infection | 16 (11) | 2 (12) | 1.000 |
| Osteomyelitis, all | 7 (5) | 1 (6) | 1.000 |
| Spondylitis | 7 (5) | 1 (6) | 1.000 |
| Arthritis, all | 10 (7) | 2 (12) | 0.620 |
| Periprosthetic joint infection |
6 (4) |
0 |
NA |
| Pneumonia | 19 (13) | 5 (29) | 0.141 |
| Empyema |
1 (1) |
0 |
NA |
| Endocarditis | 5 (4) | 0 | NA |
| Aortitis | 0 | 1 (6) | NA |
| Foreign body infection | 3 (2) | 0 | NA |
| Puerperal sepsis | 4 (3) | 0 | NA |
| Intraabdominal infection | 2 (1) | 0 | NA |
| Endophthalmitis | 2 (1) | 0 | NA |
| Bacteremia without defined focus | 14 (10) | 3 (18) | 0.397 |
*Values are no. (%) except as indicated. Severe disease was defined as treatment in the intensive care unit or death within 30 days after hospital admission. NA, not applicable. †One patient might have >1 clinical manifestations.
1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.
Page created: July 02, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.